Last reviewed · How we verify
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and total marrow irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with fludarabine phosphate and melphalan with or without total marrow irradiation in treating patients undergoing donor peripheral blood stem cell transplant for high-risk stage I or II multiple myeloma.
Details
| Lead sponsor | City of Hope Medical Center |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 18 |
| Start date | Fri Jan 28 2011 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon May 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Autologous Hematopoietic Stem Cell Transplant Recipient
- Loss of Chromosome 17p
- Plasma Cell Leukemia
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
Interventions
- bortezomib
- fludarabine phosphate
- melphalan
- total marrow irradiation
- tacrolimus
- sirolimus
- peripheral blood stem cell transplantation
- laboratory biomarker analysis
Countries
United States